Comparability study of two cagrilintide injectable presentations versus placebo for weight management

Phase 3, randomised, double-blind trial of cagrilintide in obesity and Overweight (3 arms), sponsored by Novo Nordisk. Primary endpoint: Relative change in body weight from baseline to week 26. Planned start Jul 2026; status: authorised.